Month: May 2023

Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023 Commenced enrollment in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab)PRINCETON, N.J., May 10, 2023 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update. “We are pleased with the ongoing progress in the PYNNACLE study of PC14586, a first-in-class p53 Y220C reactivator, in patients with advanced solid tumors. We look forward...

Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer Initiated IND and Phase 1a Study for NXP900 Pending In-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR Conference Demonstrates Potential of NXP800 in the Treatment of CholangiocarcinomaFORT LEE, N.J., May 10, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2023 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis commented, “In the last few months, the Nuvectis...

Record First Quarter Total Revenue of $41 Million MACI Revenue Increased 32% to $34.2 Million Full-Year 2023 Revenue Guidance Raised to $184-$192 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2023, and provided updated full-year 2023 financial guidance. First Quarter 2023 Financial HighlightsTotal net revenue of $41.0 million MACI® net revenue of $34.2 million and Epicel® net revenue of $6.8 million Gross margin of 65% Net loss of $7.5 million, or $0.16 per diluted share Non-GAAP adjusted EBITDA of $1.7 million Operating cash flow of $7.9 million As of March...

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the first quarter ended March 31, 2023. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:As at March 31, 2023, Book Value per Share of the Company was $11.22, compared with $11.28 as at December 31, 2022.The Company’s cash position as at March 31, 2023, was $30.2 million or $3.33 per share.To date, the Company has completed eight investments with fair value totalling $70.2 million or $7.74 per share as at March 31, 2023, into the following:Prove Identity, Inc. (cyber-security) Newfront Insurance, Inc. (insurance & benefits) Locus Robotics, Inc. (robotics) Omio, Inc. (travel & leisure) SpaceX (space...

HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced financial results for the quarter ended March 31, 2023. Second Quarter 2023 HighlightsRevenue of $569 million for the second quarter of fiscal 2023, an increase of 13% compared with $502 million for the same quarter of fiscal 2022 Operating income of $31.6 million for the second quarter of fiscal 2023, compared with an operating loss of $4.9 million for the same quarter of fiscal 2022 Net income attributable to IES of $21.6 million, or $0.92 per share for the second quarter of fiscal 2023, compared with a net loss of $5.4 million, or $0.30 per share for the same quarter of fiscal 2022 Adjusted net income attributable to IES (a non-GAAP financial measure, as defined below) of $24.6 million or $1.07 per share...

Successful Pivot to Fully Electric Off-road Vehicles Continued to Boost Revenue High Gross Margin Driven by Fully Electric Crossover Golf CartsJINHUA, CHINA, May 10, 2023 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company”, “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the first quarter of 2023. First Quarter HighlightsTotal revenues of $22.9 million compared to $24.9 million in the same period of 2022.Off-road vehicles and associated parts sales increased by 94.0% to $20.8 million, compared to $10.7 million in the same period of 2022.EV products and parts sales totaled $0.03 million, compared with $4.0 million total for the first quarter of 2022, attributed to the Company’s shift in focus towards production of off-road vehicles with higher demand and better margins.Electric...

Delivered 24% revenue and 37% Adjusted EBITDA growth U.S. segment revenue grew 55% with positive Adjusted EBITDA for third consecutive quarterAnnual outlook reaffirmed with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA ST. GALLEN, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global technology company focused on enabling next generation engagement in sports through providing business-to-business solutions to the global sports betting industry, today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 HighlightsRevenue in the first quarter of 2023 increased 24% to €207.6 million ($226.2 million)1 compared with the first quarter of 2022. The RoW Betting segment, accounting for 52% of total revenue,...

Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company’s focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ETHOUSTON, May 10, 2023 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “Our TCR-T Library Phase 1/2 trial continues...

GARDEN CITY, N.Y., May 10, 2023 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today reported its financial results for the quarter ended March 31, 2023. Rob Kay, Lifetime’s Chief Executive Officer, commented, “Our results this quarter were in line with our expectations, with our core business continuing to deliver solid performance in the face of a challenging macroeconomic and consumer spending environment. Our first quarter results reflect the continued impact of reduced orders as our customers focused on rightsizing their inventory levels, with the majority of these impacts coming from our largest customers. While inflationary and macroeconomic pressures contributed to weaker end market demand, our international...